Sanofi/Regeneron win 1st US PCSK9 OK with Praluent
This article was originally published in Scrip
Sanofi and Regeneron Pharmaceuticals on 24 July pulled off the first US approval of a proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor – gaining the FDA's nod for Praluent (alirocumab).
You may also be interested in...
The battle for PCSK9 inhibitor market share continues with Amgen’s Repatha outselling Praluent, but a now-ended patent dispute no longer threatens Regeneron’s ability to sell its product in the US.
Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.